Triple combination targeting PI3K, ER, and CDK4/6 inhibits growth of ER-positive breast cancer resistant to fulvestrant and CDK4/6 or PI3K inhibitor.
Leena KarimiCarla L AlvesMikkel G TerpMartina TuttolomondoNeil PortmanSidse EhmsenLene E JohansenMartin BakElgene LimHenrik Jørn DitzelPublished in: Cancer communications (London, England) (2023)